JP2007530068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530068A5 JP2007530068A5 JP2007505621A JP2007505621A JP2007530068A5 JP 2007530068 A5 JP2007530068 A5 JP 2007530068A5 JP 2007505621 A JP2007505621 A JP 2007505621A JP 2007505621 A JP2007505621 A JP 2007505621A JP 2007530068 A5 JP2007530068 A5 JP 2007530068A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- hosm
- interaction
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000040430 polynucleotide Human genes 0.000 claims 25
- 108091033319 polynucleotide Proteins 0.000 claims 25
- 239000002157 polynucleotide Substances 0.000 claims 25
- 230000001225 therapeutic effect Effects 0.000 claims 23
- 230000003993 interaction Effects 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 16
- 241000282414 Homo sapiens Species 0.000 claims 11
- 238000000034 method Methods 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 101001042362 Homo sapiens Leukemia inhibitory factor receptor Proteins 0.000 claims 5
- 101000586302 Homo sapiens Oncostatin-M-specific receptor subunit beta Proteins 0.000 claims 5
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 claims 5
- 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 claims 5
- 238000002965 ELISA Methods 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 230000002917 arthritic effect Effects 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 210000001179 synovial fluid Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 241000288906 Primates Species 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000022983 regulation of cell cycle Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0407193A GB0407193D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
| GB0407193.2 | 2004-03-30 | ||
| GB0407197A GB0407197D0 (en) | 2004-03-30 | 2004-03-30 | Immunoglobulins |
| GB0407197.3 | 2004-03-30 | ||
| PCT/GB2005/001147 WO2005095457A2 (en) | 2004-03-30 | 2005-03-29 | Immunoglobulins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530068A JP2007530068A (ja) | 2007-11-01 |
| JP2007530068A5 true JP2007530068A5 (https=) | 2008-04-24 |
| JP4809828B2 JP4809828B2 (ja) | 2011-11-09 |
Family
ID=35064447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505621A Expired - Fee Related JP4809828B2 (ja) | 2004-03-30 | 2005-03-29 | 免疫グロブリン |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7858753B2 (https=) |
| EP (2) | EP1730191B1 (https=) |
| JP (1) | JP4809828B2 (https=) |
| KR (1) | KR100942849B1 (https=) |
| AR (1) | AR048516A1 (https=) |
| AT (1) | ATE515515T1 (https=) |
| AU (1) | AU2005229457B2 (https=) |
| BR (1) | BRPI0509367A (https=) |
| CA (1) | CA2562953A1 (https=) |
| CY (1) | CY1112192T1 (https=) |
| DK (1) | DK1730191T3 (https=) |
| HR (1) | HRP20110657T1 (https=) |
| IL (1) | IL178119A0 (https=) |
| MA (1) | MA28541B1 (https=) |
| NO (1) | NO20064886L (https=) |
| NZ (1) | NZ550225A (https=) |
| PE (1) | PE20060287A1 (https=) |
| PL (1) | PL1730191T3 (https=) |
| PT (1) | PT1730191E (https=) |
| RU (5) | RU2429245C2 (https=) |
| SG (1) | SG151292A1 (https=) |
| SI (1) | SI1730191T1 (https=) |
| TW (1) | TWI365746B (https=) |
| WO (1) | WO2005095457A2 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
| WO2007098547A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| CA2652733C (en) | 2006-05-25 | 2016-06-21 | Glaxo Group Limited | Modified humanised anti-interleukin-18 antibodies |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| BRPI0910509B8 (pt) | 2008-07-10 | 2021-05-25 | Toray Industries | uso do anticorpo, anticorpo e composição farmacêutica |
| KR101638490B1 (ko) | 2008-08-05 | 2016-07-11 | 도레이 카부시키가이샤 | 암의 치료 및 예방용 의약 조성물 |
| AU2009288354A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
| US8309688B2 (en) | 2008-12-30 | 2012-11-13 | Centocor Ortho Biotech Inc. | Monkey homolog of human oncostatin M and methods of use thereof |
| EP2258723A1 (en) * | 2009-06-02 | 2010-12-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Treatment of oncostatin M receptor ß mediated heart failure |
| KR101842893B1 (ko) | 2010-02-04 | 2018-03-28 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| MX342291B (es) | 2010-02-04 | 2016-09-23 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| HUE025678T2 (en) | 2010-02-04 | 2016-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| RU2598258C2 (ru) | 2010-02-04 | 2016-09-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| MX340015B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| PH12013500703A1 (en) * | 2010-10-13 | 2013-05-20 | Janssen Biotech Inc | Human oncostatin m antibodies and methods of use |
| AR083937A1 (es) * | 2010-11-23 | 2013-04-10 | Glaxo Group Ltd | Proteinas de union a antigenos |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| PT2740794T (pt) | 2011-08-04 | 2018-06-14 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| PT2818483T (pt) | 2012-02-21 | 2017-10-09 | Toray Industries | Composição medicinal para tratamento e/ou prevenção de cancro |
| HUE044611T2 (hu) | 2012-02-21 | 2019-11-28 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| KR102155531B1 (ko) | 2012-03-30 | 2020-09-15 | 도레이 카부시키가이샤 | 간암의 치료 및/또는 예방용 의약 조성물 |
| PT2832366T (pt) | 2012-03-30 | 2018-01-25 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar |
| SI3456743T1 (sl) | 2013-05-30 | 2022-01-31 | Kiniksa Pharmaceuticals, Ltd. | Proteini, ki vežejo antigen receptorja onkostatina M |
| ES2704909T3 (es) | 2013-08-09 | 2019-03-20 | Toray Industries | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| US9550828B2 (en) | 2013-09-05 | 2017-01-24 | Boise State University | Oncostatin M (OSM) antagonists for preventing cancer metastasis and IL-6 related disorders |
| BR112016015140A2 (pt) | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| PL3110434T3 (pl) * | 2014-02-24 | 2019-01-31 | Takeda Gmbh | Białka fuzyjne uti |
| US20170327573A1 (en) * | 2014-09-24 | 2017-11-16 | Universitá Degli Studi Di Padova | Composition to induce bone marrow stem cell mobilization |
| WO2016120387A1 (en) * | 2015-01-29 | 2016-08-04 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| RU2767329C2 (ru) | 2016-02-06 | 2022-03-17 | Эпимаб Биотерапьютикс, Инк. | Иммуноглобулин с тандемными fab-фрагментами и варианты его применения |
| BR112018069318A2 (pt) | 2016-03-28 | 2019-01-22 | Toray Industries | composição farmacêutica para tratamento e/ou prevenção de um câncer, anticorpo ou fragmento do mesmo, combinação farmacêutica para tratamento e/ou prevenção de um câncer e método para tratar e/ou prevenir um câncer |
| GB201614627D0 (en) * | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
| MX2020011588A (es) | 2018-05-03 | 2020-12-07 | Shanghai Epimab Biotherapeutics Co Ltd | Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas. |
| FR3090637A1 (fr) * | 2018-12-21 | 2020-06-26 | Universite De Poitiers | Protéine de liaison spécifique capable de se lier spécifiquement à l’oncostatine M humaine (hOSM) et ses utilisations. |
| US11633457B2 (en) | 2019-04-11 | 2023-04-25 | Boise State University | Pharmaceutical compositions comprising oncostatin m (OSM) antagonist derivatives and methods of use |
| TWI904261B (zh) | 2020-10-19 | 2025-11-11 | 美商碩騰服務公司 | 犬及貓抑瘤素M受體β之抗體及其用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| CA2114015C (en) | 1991-07-25 | 2002-12-10 | Roland A. Newman | Recombinant antibodies for human therapy |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| EP0656064B1 (en) | 1992-08-17 | 1997-03-05 | Genentech, Inc. | Bispecific immunoadhesins |
| AU6852594A (en) | 1993-06-03 | 1995-01-03 | Therapeutic Antibodies Inc. | Production of antibody fragments |
| JP3622208B2 (ja) | 1993-06-11 | 2005-02-23 | 東ソー株式会社 | 骨粗鬆症治療方法及び治療薬 |
| US5429746A (en) | 1994-02-22 | 1995-07-04 | Smith Kline Beecham Corporation | Antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| GB9806530D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| WO1999055369A1 (en) | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
-
2005
- 2005-03-29 HR HR20110657T patent/HRP20110657T1/hr unknown
- 2005-03-29 SI SI200531371T patent/SI1730191T1/sl unknown
- 2005-03-29 PT PT05733043T patent/PT1730191E/pt unknown
- 2005-03-29 BR BRPI0509367-8A patent/BRPI0509367A/pt not_active IP Right Cessation
- 2005-03-29 US US10/594,293 patent/US7858753B2/en not_active Expired - Fee Related
- 2005-03-29 CA CA002562953A patent/CA2562953A1/en not_active Abandoned
- 2005-03-29 DK DK05733043.3T patent/DK1730191T3/da active
- 2005-03-29 AT AT05733043T patent/ATE515515T1/de active
- 2005-03-29 PL PL05733043T patent/PL1730191T3/pl unknown
- 2005-03-29 EP EP05733043A patent/EP1730191B1/en not_active Expired - Lifetime
- 2005-03-29 WO PCT/GB2005/001147 patent/WO2005095457A2/en not_active Ceased
- 2005-03-29 JP JP2007505621A patent/JP4809828B2/ja not_active Expired - Fee Related
- 2005-03-29 KR KR1020067022671A patent/KR100942849B1/ko not_active Expired - Fee Related
- 2005-03-29 SG SG200901959-7A patent/SG151292A1/en unknown
- 2005-03-29 PE PE2005000360A patent/PE20060287A1/es not_active Application Discontinuation
- 2005-03-29 AU AU2005229457A patent/AU2005229457B2/en not_active Ceased
- 2005-03-29 EP EP11167424A patent/EP2404935A1/en not_active Withdrawn
- 2005-03-29 RU RU2006134477/10A patent/RU2429245C2/ru not_active IP Right Cessation
- 2005-03-29 NZ NZ550225A patent/NZ550225A/en not_active IP Right Cessation
- 2005-03-30 TW TW094110049A patent/TWI365746B/zh not_active IP Right Cessation
- 2005-03-30 AR ARP050101233A patent/AR048516A1/es unknown
-
2006
- 2006-09-14 IL IL178119A patent/IL178119A0/en unknown
- 2006-10-18 MA MA29397A patent/MA28541B1/fr unknown
- 2006-10-26 NO NO20064886A patent/NO20064886L/no not_active Application Discontinuation
-
2009
- 2009-03-10 RU RU2009108147/10A patent/RU2009108147A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108148/10A patent/RU2009108148A/ru not_active Application Discontinuation
- 2009-03-10 RU RU2009108149/10A patent/RU2009108149A/ru not_active Application Discontinuation
-
2010
- 2010-11-16 US US12/947,371 patent/US20110245470A1/en not_active Abandoned
-
2011
- 2011-05-30 RU RU2011121419/10A patent/RU2011121419A/ru not_active Application Discontinuation
- 2011-09-29 CY CY20111100943T patent/CY1112192T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530068A5 (https=) | ||
| RU2006134477A (ru) | Иммуноглобулины | |
| JP7610541B2 (ja) | 結合タンパク質及びその使用方法 | |
| CN109517065B (zh) | Il-18结合分子 | |
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| US20240353422A1 (en) | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP6513657B2 (ja) | Il−17a結合剤およびその用途 | |
| JP2021101720A5 (https=) | ||
| KR20180048712A (ko) | Tl1a에 특이적으로 결합하는 항체 | |
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| EP2771362A1 (en) | Immunobinders directed against tnf | |
| JP2020521504A (ja) | 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用 | |
| KR20200106056A (ko) | 자가면역 질환 및 암을 치료하기 위한 항-cxcl13 항체 | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| CN113677701B (zh) | 产生亲合结合多特异性抗体的方法 | |
| TW202334220A (zh) | 人類腫瘤壞死因子α抗體 | |
| WO2013186630A2 (en) | Humanized antibodies to ca215 | |
| GB2600273A (en) | Antibody to leptin receptor | |
| US20190225680A1 (en) | Tenascin Epitope and Antibodies Thereto | |
| US10584175B2 (en) | FN14-binding proteins and uses thereof | |
| CN114106163A (zh) | SARS-CoV-2病毒中和抗体及其用途 | |
| AU2024319932A1 (en) | Btn3a-binding protein and medical uses thereof | |
| RU2779128C2 (ru) | Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение | |
| CN120476139A (zh) | 抗tslp抗体及其应用 |